What Cardisio does

Cardisio GmbH is a Frankfurt-based health technology company that has built Cardisiography (CSG), an AI-powered non-invasive screening system for coronary heart disease, atrial fibrillation, heart failure, and structural heart abnormalities. The platform combines a medical-grade Cardisiograph hardware device (a five-electrode data collector compliant with EN 55032:2015 Class B and related standards) with the Cardisio Cloud, a CE-certified Class 1 web service that applies a proprietary algorithm to analyze 583 parameters per heartbeat from vectorcardiography data and deliver a 19-channel ECG derivation (ESC-guideline compliant) plus a 3D representation of cardiac electrical activity within roughly five minutes. Sensitivity for coronary heart disease exceeds 90–95% in published clinical studies, materially above the 45–50% benchmark for conventional stress ECG.

The company sells to general practitioners and cardiology specialists in Germany, with 1,300+ physicians and 400,000+ screenings recorded as of March 2026. Revenue is generated through three streams: Cardisiograph hardware sales, recurring revenue from disposable electrodes (five per measurement) via the Cardisio Shop, and Cardisio Cloud subscriptions. Services in Germany are billable under GOÄ codes 657 and A658 and within HzV contracts, anchoring the model in established reimbursement pathways. Beyond Germany, Cardisio has expanded into Spain through a distribution partnership with Glintt (pharmacy-based testing in Madrid, Alicante, Murcia), into the UK through wholly-owned Cardisio UK Limited and the SBRI Healthcare program, and is pursuing FDA clearance for the US market.

The company holds ISO 13485:2021 and ISO 9001:2015 certifications, is GDPR-compliant, and has secured multiple peer-reviewed validations (Nature Scientific Reports, Journal of Electrocardiology, BJGP Open, Circulation). Backed by private investors from the US and Germany and LEA Partners, Cardisio operates with an 11–50 employee footprint from its Frankfurt headquarters, with a regional presence in Madrid. The platform's AI maturity is evidenced by the proprietary 583-parameter analysis, continuous cloud-based algorithm updates trained on a 400,000+ procedure dataset, and active research collaborations with Charité, Heidelberg University Hospital, and HDZ-NRW.

Name

Cardisio

Legal name

Cardisio GmbH

Website

https://cardis.io

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Cardisio is a Frankfurt-based health technology company that offers AI-powered Cardisiography, a non-invasive screening test combining vectorcardiography and machine learning to detect coronary and structural heart disease in primary care and cardiology practices.

Ownership category

akta.pro rank

Product category

AI Cardiac Diagnostic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Instruments For Meas & Testing Of Electricity & Elec Signals (3825)

akta.pro primary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

akta.pro secondary industries

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Preventive Cardiology & Lipidology (HLAKABAF)

Keywords

• Cardiac screening devices
• AI cardiac diagnostics
• Vectorcardiography technology
• Non-invasive heart monitoring
• Electrocardiogram medical devices

Headquarters

HQ city

Frankfurt

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Cardisiography System Sales: Sale of Cardisiograph hardware device (medical data collector) to healthcare practices. Practices also require disposable electrodes (5 per measurement) as consumables.
2. Cardisio Cloud Subscription: Cloud-based AI analysis service accessed via web portal. The Cardisio Cloud is classified as a Class 1 medical device under MDD. Subscription likely required for ongoing analysis and report generation.
3. Insurance Reimbursement (Germany): Billable through GOÄ ZIFFERN 657 and A658 codes, and covered under HzV (Hausarztzentrierte Versorgung) contracts in Germany. Revenue flows through established healthcare billing systems.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels10 records

Core offering

Cardisio develops and sells Cardisiography (CSG), an AI-powered non-invasive cardiac screening system combining a 5-electrode vectorcardiography hardware device (Cardisiograph) with cloud-based AI analysis (Cardisio Cloud). The system generates a 3D-EKG and 19-channel ECG in under 10 minutes, detecting ischemia, atrial fibrillation, and structural heart disease with >90% sensitivity. The product is sold to healthcare practices, complemented by consumable electrodes and recurring cloud subscriptions.

Product overview

Cardisio offers a unified medical diagnostic ecosystem centered on Cardisiography (CSG), an AI-powered non-invasive heart disease screening technology. The core offering combines the Cardisiograph hardware device (data collector with 5-electrode system), Cardisio Cloud web service (AI analysis engine), and Cardisio App (results access) into a single diagnostic workflow. Cardisiography produces a 3D-EKG and 19-channel ECG in under 10 minutes, detecting ischemia, arrhythmias, and structural heart disease with >95% sensitivity. Supporting services include CSG Schulungen (professional training), Learning Center (self-paced tutorials), Cardisio Shop (accessories), and cardiocheckup.health (patient scheduling portal). The CSG-Index proprietary metric differentiates cardiac risk with superior accuracy compared to conventional risk scores.

Differentiator

Problem solved

Functional benefit

Brands

• Cardisio Cloud: Cloud-based web service platform for Cardisiography analysis and reporting. The web service is classified as a Class 1 medical product according to MDD.

Products and services

• Cardisiography (CSG) AI-powered non-invasive heart disease screening technology using digital vectorcardiography (VCG) to create a 3D-EKG and 19-channel ECG derivation (ESC-guideline conformant) for detecting ischemia (CHD), arrhythmias, atrial fibrillation, and structural heart diseases in under 10 minutes. Designed for general practitioners and cardiologists.
• Cardisiograph (Data Collector) Medical-grade hardware data collector device with electrode cables for the 5-electrode measurement system. Captures 4-minute cardiac signal recordings that are transmitted to the Cardisio Cloud for AI analysis. Sold to healthcare practices as the hardware component of the Cardisiography system.
• Cardisio Cloud Cloud-based web service (Class 1 medical device per MDD) that receives patient cardiac data from the Cardisiograph device and processes it through the AI algorithm to generate diagnostic reports within 5 minutes via secure, GDPR-compliant cloud infrastructure. Accessed via subscription by healthcare practices.
• Cardisio App Mobile application for accessing and managing Cardisiography test results. Enables physicians and patients to view diagnostic reports, track cardiac screening history, and access results from the Cardisio Cloud platform.
• Cardisio Shop (Electrodes & Accessories) Online shop selling consumable disposable electrodes (5 electrodes required per cardisiography measurement) and practice marketing materials to healthcare practices operating Cardisiograph devices. Operates on a pay-as-you-go unit pricing basis.

Quantifiable outcome

• Sensitivity >95% for detecting coronary heart disease (KHK) compared to stress ECG at 45-50%
• +7 more outcomes

Named customers14 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• SBRI Healthcare / NHS EnglandcoreStrategic or Co-development Partner · 1 January 2023SBRI Healthcare awarded £3.3M to eight cardiovascular innovations including Cardisio. Partnership with NHS England and Academic Health Science Networks to assess community-based heart testing in primary care settings. Validation study conducted in West Midlands GP practices, pharmacies, and community health centers. Study published in British Journal of General Practice 2025.
• Charité - Universitätsmedizin BerlincoreStrategic or Co-development PartnerAcademic research partnership for clinical validation of Cardisiography. Listed as research partner on website.
• Universitätsklinikum HeidelbergcoreStrategic or Co-development PartnerAcademic medical center partnership for VCG algorithm development. Multiple studies published including LV hypertrophy detection (2025), LV ejection fraction assessment. Heidelberg University Hospital conducted prospective case-control studies with 245+ participants.
• Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ-NRW)coreStrategic or Co-development PartnerHeart and Diabetes Center Bad Oeynhausen partnership. Comparison studies of Cardisiography with myocardial SPECT and coronary angiography. NPV of 98% demonstrated in pre-diagnostic testing.
• Sana Heart Center CottbusminorStrategic or Co-development PartnerValidation study showing 95.4% sensitivity, 90% specificity for CHD detection vs coronary angiography. Study led by Dr. Temirlan Erkenov.
• GlinttcoreChannel Partner/ Reseller/ DistributorSpanish distribution partner for Cardisiography. Glintt manages pharmacy network and testing locations across Spain including Madrid, Alicante, Murcia regions. Cooperation agreement for cardiosiography examinations and locations.
• German Society for Cardiology (DGK)coreStrategic or Co-development PartnerProfessional society endorsement. Multiple presentations at DGK Annual Meetings and Heart Days (2023, 2024, 2025). Research findings on 5L3DVCG-AI presented.
• European Society of Cardiology (ESC)coreStrategic or Co-development PartnerProfessional society affiliation. ESC congress presentation 2023 on CSG vs CVRF score comparison. ESC guidelines compliant (19-channel ECG including V7-V9 and Vr3-Vr6 leads).
• American Heart Association (AHA)coreStrategic or Co-development PartnerProfessional society affiliation. AHA Scientific Sessions 2023 presentation published in Circulation. Validation of AI-based 5-lead 3D VCG vs 12-lead ECG.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• AliveCor: AliveCor (KardiaMobile) produces AI-enabled 6-lead ECG devices for AF and cardiac screening targeted at primary care and consumers. It is the closest direct peer to Cardisio in terms of AI-ECG-based, non-invasive cardiac screening sold to physicians and patients.
• Eko Health: Eko Health builds AI-enabled digital stethoscopes and ECG devices with FDA-cleared cardiac analysis algorithms for primary care and cardiology. Comparable to Cardisio as a hardware-plus-AI platform focused on early cardiac detection in non-specialist settings.
• iRhythm Technologies: iRhythm (Zio) provides AI-driven ambulatory cardiac monitoring with cloud-based analysis, focused on arrhythmia detection. Comparable to Cardisio in the use of AI/cloud-based cardiac signal analysis, though concentrated on long-term rhythm monitoring rather than ischemic screening.

Emerging players

• HeartFlow: HeartFlow offers AI-based non-invasive coronary diagnostics (FFR-CT) for coronary artery disease. Overlaps with Cardisio on non-invasive ischemic heart disease detection, but uses CT imaging rather than electrophysiology and serves a different point in the diagnostic pathway (specialist referral vs. primary care screening).
• CardioComm Solutions: CardioComm provides ECG management software and cloud-based cardiac monitoring with AI-assisted analysis for primary care and remote screening. Comparable to Cardisio as a smaller, software-forward cardiac diagnostics vendor, though with a focus on ECG data management rather than novel electrophysiology modalities.

Broad incumbents

• GE HealthCare: GE HealthCare's MAC-series resting ECG and stress ECG systems, augmented with AI-based interpretation (e.g., Mural/ECG algorithms), dominate hospital cardiology purchasing. It is a broad incumbent whose installed base and AI roadmap represent both competition and a potential integration partner for Cardisio-style analytics.
• Philips: Philips' PageWriter TC and Intellispace ECG AI cardiac analytics serve hospitals and large cardiology practices globally. Comparable as a broad incumbent with overlapping AI-ECG capabilities, larger salesforce, and deeper hospital channel relationships than Cardisio.
• Mindray: Mindray is a large Chinese-origin medical device manufacturer offering ECG, patient monitoring, and diagnostic cardiology equipment globally. Comparable as a broad incumbent in the ECG/cardiac diagnostics category with growing AI-based interpretation features.
• Boston Scientific (Preventice Solutions): Boston Scientific, via its Preventice acquisition (BodyGuardian, ECG-as-a-Service), offers AI-enabled ambulatory cardiac monitoring. Comparable to Cardisio in cloud-based cardiac signal analysis and remote monitoring, though operating at a much larger scale and focused on ambulatory rhythm monitoring rather than primary care ischemic screening.

Regional players

• Schiller AG: Schiller is a Swiss/European manufacturer of Cardiovit resting ECG, Holter, and stress-test systems with a strong presence in German-speaking primary care. Directly comparable to Cardisio on the ECG hardware side and a likely regional incumbent in the same physician channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCCfew5JrKfTROcxeRAfYQ0Q
• Xx.com/Crdsio
• Facebookfacebook.com/Cardisio

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardisio